Alicia Caitlin Smart, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bile Duct Neoplasms | 2 | 2019 | 567 | 0.970 |
Why?
|
| Cholangiocarcinoma | 2 | 2019 | 516 | 0.970 |
Why?
|
| Sex Reassignment Surgery | 1 | 2023 | 130 | 0.750 |
Why?
|
| Introns | 1 | 2018 | 991 | 0.530 |
Why?
|
| Brachytherapy | 1 | 2020 | 1246 | 0.420 |
Why?
|
| Epitopes | 1 | 2018 | 2569 | 0.400 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1927 | 0.390 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1351 | 0.380 |
Why?
|
| Thrombosis | 1 | 2023 | 2966 | 0.340 |
Why?
|
| Models, Genetic | 1 | 2018 | 3493 | 0.310 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 6347 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5249 | 0.270 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5724 | 0.250 |
Why?
|
| Computer Simulation | 1 | 2018 | 6191 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 9185 | 0.250 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 2876 | 0.230 |
Why?
|
| Mesenteric Veins | 1 | 2023 | 89 | 0.230 |
Why?
|
| Neoplasms | 2 | 2023 | 21596 | 0.210 |
Why?
|
| Portal Vein | 1 | 2023 | 437 | 0.190 |
Why?
|
| Anal Canal | 1 | 2023 | 376 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2020 | 108 | 0.180 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 656 | 0.170 |
Why?
|
| Homosexuality, Female | 1 | 2021 | 157 | 0.170 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2020 | 221 | 0.160 |
Why?
|
| Vagina | 1 | 2023 | 825 | 0.160 |
Why?
|
| Epitope Mapping | 1 | 2018 | 311 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 450 | 0.140 |
Why?
|
| Fluorouracil | 1 | 2019 | 1615 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 1769 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2019 | 2615 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1178 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77098 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3471 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 1021 | 0.100 |
Why?
|
| RNA | 1 | 2018 | 2747 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8621 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12242 | 0.070 |
Why?
|
| Survival Rate | 1 | 2020 | 12773 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11001 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 57683 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16665 | 0.060 |
Why?
|
| Humans | 8 | 2023 | 742088 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11472 | 0.040 |
Why?
|
| Female | 4 | 2023 | 379592 | 0.040 |
Why?
|
| Aged | 2 | 2020 | 162944 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 40450 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 195 | 0.040 |
Why?
|
| Middle Aged | 2 | 2020 | 213127 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 213712 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 351 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 62966 | 0.030 |
Why?
|
| Male | 2 | 2023 | 349538 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1866 | 0.030 |
Why?
|
| Language | 1 | 2021 | 1458 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2017 | 828 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 1670 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 6313 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 5975 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 11363 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5163 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7317 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5304 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 81045 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 168561 | 0.000 |
Why?
|